- Home
- CBRE vs TOVX Comparison
CBRE vs TOVX Comparison
Compare CBRE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- TOVX
- Stock Information
- Founded
- CBRE 1906
- TOVX 2001
- Country
- CBRE United States
- TOVX United States
- Employees
- CBRE N/A
- TOVX N/A
- Industry
- CBRE Real Estate
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CBRE Finance
- TOVX Health Care
- Exchange
- CBRE Nasdaq
- TOVX Nasdaq
- Market Cap
- CBRE 41.3B
- TOVX 3.8M
- IPO Year
- CBRE 2004
- TOVX 2006
- Fundamental
- Price
- CBRE $139.46
- TOVX $0.49
- Analyst Decision
- CBRE Buy
- TOVX Hold
- Analyst Count
- CBRE 9
- TOVX 1
- Target Price
- CBRE $152.78
- TOVX N/A
- AVG Volume (30 Days)
- CBRE 1.4M
- TOVX 169.1K
- Earning Date
- CBRE 07-29-2025
- TOVX 08-12-2025
- Dividend Yield
- CBRE N/A
- TOVX N/A
- EPS Growth
- CBRE 2.39
- TOVX N/A
- EPS
- CBRE 3.28
- TOVX N/A
- Revenue
- CBRE $36,742,000,000.00
- TOVX N/A
- Revenue This Year
- CBRE $14.26
- TOVX N/A
- Revenue Next Year
- CBRE $9.11
- TOVX N/A
- P/E Ratio
- CBRE $42.55
- TOVX N/A
- Revenue Growth
- CBRE 13.15
- TOVX N/A
- 52 Week Low
- CBRE $96.38
- TOVX $0.40
- 52 Week High
- CBRE $147.75
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- CBRE 56.01
- TOVX 50.56
- Support Level
- CBRE $135.44
- TOVX $0.45
- Resistance Level
- CBRE $141.62
- TOVX $0.48
- Average True Range (ATR)
- CBRE 2.51
- TOVX 0.03
- MACD
- CBRE -0.69
- TOVX 0.01
- Stochastic Oscillator
- CBRE 46.10
- TOVX 79.33
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.